DexCom, Inc. (DXCM) Shares Bought by Arizona State Retirement System

Arizona State Retirement System boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 2.8% in the first quarter, HoldingsChannel.com reports. The firm owned 8,084 shares of the medical device company’s stock after acquiring an additional 219 shares during the period. Arizona State Retirement System’s holdings in DexCom were worth $963,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of DexCom by 8.7% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,011 shares of the medical device company’s stock valued at $2,383,000 after acquiring an additional 1,595 shares during the period. Quadrant Capital Group LLC lifted its stake in shares of DexCom by 246.7% during the 1st quarter. Quadrant Capital Group LLC now owns 631 shares of the medical device company’s stock valued at $73,000 after buying an additional 449 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in shares of DexCom by 19.8% during the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 30,914 shares of the medical device company’s stock valued at $3,682,000 after buying an additional 5,114 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of DexCom by 6.6% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,801 shares of the medical device company’s stock valued at $1,286,000 after buying an additional 667 shares in the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of DexCom by 50.4% during the 1st quarter. Bank of Montreal Can now owns 100,031 shares of the medical device company’s stock valued at $11,913,000 after buying an additional 33,504 shares in the last quarter. 96.15% of the stock is owned by institutional investors and hedge funds.

Shares of DXCM stock opened at $121.49 on Thursday. The firm has a market capitalization of $10.58 billion, a price-to-earnings ratio of 404.97 and a beta of 0.73. DexCom, Inc. has a 52 week low of $85.76 and a 52 week high of $156.16. The company has a debt-to-equity ratio of 1.57, a quick ratio of 6.75 and a current ratio of 7.18.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.12. The business had revenue of $280.50 million for the quarter, compared to analysts’ expectations of $246.10 million. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The business’s quarterly revenue was up 52.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.30) EPS. As a group, equities analysts expect that DexCom, Inc. will post 0.77 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of DexCom from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a research note on Tuesday, April 30th. Piper Jaffray Companies lifted their target price on shares of DexCom to $173.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. BidaskClub cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday, March 26th. Raymond James lowered their target price on shares of DexCom from $160.00 to $150.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. Finally, BMO Capital Markets lifted their target price on shares of DexCom from $167.00 to $172.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $152.25.

In other news, insider Andrew K. Balo sold 10,917 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $142.79, for a total transaction of $1,558,838.43. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $115.05, for a total transaction of $46,020.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 96,530 shares of company stock worth $13,258,066. Corporate insiders own 1.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) Shares Bought by Arizona State Retirement System” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.wkrb13.com/2019/05/16/dexcom-inc-dxcm-shares-bought-by-arizona-state-retirement-system.html.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Systematic Risk and Investors

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.